Skip to main content

11 Result(s)

within Takahiro Ebata Remove this filter

and

  1. No Access

    Article

    HSD17B4 methylation enhances glucose dependence of BT-474 breast cancer cells and increases lapatinib sensitivity

    HER2-positive breast cancer has a high chance of achieving pathological complete response when HSD17B4, responsible for peroxisomal β-oxidation of very long-chain fatty acids (VLCFA) and estradiol, is methylation...

    Nobuaki Arai, Naoko Hattori, Satoshi Yamashita… in Breast Cancer Research and Treatment (2023)

  2. No Access

    Article

    A feasibility study of lenvatinib plus pembrolizumab in Japanese patients with advanced solid tumors

    Combination treatment using lenvatinib (a multikinase inhibitor) plus pembrolizumab (a programmed death-1 immune checkpoint inhibitor) has shown efficacy in the treatment of endometrial and renal cell cancers....

    Shigehisa Kitano, Yutaka Fujiwara, Toshio Shimizu… in Cancer Chemotherapy and Pharmacology (2022)

  3. No Access

    Article

    DNA methylation marker to estimate ovarian cancer cell fraction

    Evaluation of a cancer cell fraction is important for accurate molecular analysis, and pathological analysis is the gold standard for evaluation. Despite the potential convenience, no established molecular mar...

    Takahiro Ebata, Satoshi Yamashita, Hideyuki Takeshima, Hiroshi Yoshida… in Medical Oncology (2022)

  4. No Access

    Article

    Risk factors for skeletal-related events in non-small cell lung cancer patients treated with bone-modifying agents

    The risk factors for skeletal-related events (SREs) among non-small cell lung cancer (NSCLC) patients during treatment with bone-modifying agents (BMAs) are not yet well-understood.

    Go Saito, Takahiro Ebata, Tsukasa Ishiwata, Shunichiro Iwasawa… in Supportive Care in Cancer (2021)

  5. Article

    Open Access

    Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies

    Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced mali...

    Shigehisa Kitano, Toshio Shimizu, Takafumi Koyama… in Cancer Chemotherapy and Pharmacology (2021)

    Download PDF (2400 KB) View Article

  6. Article

    Open Access

    Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours

    Navoximod (GDC-0919) is a small molecule inhibitor of indoleamine-2,3-dioxygenase 1. This study investigated the safety, tolerability and pharmacokinetics of navoximod alone and in combination with atezolizuma...

    Takahiro Ebata, Toshio Shimizu, Yutaka Fujiwara, Kenji Tamura… in Investigational New Drugs (2020)

    Download PDF (748 KB) View Article

  7. No Access

    Article

    Improved survival among patients enrolled in oncology phase 1 trials in recent decades

    This study aimed to compare the survival of patients enrolled in phase 1 trials in recent decades.

    Takahiro Ebata, Toshio Shimizu, Takafumi Koyama… in Cancer Chemotherapy and Pharmacology (2020)

  8. No Access

    Article

    Feasibility of initial treatment in elderly patients with ovarian cancer in Japan: a retrospective study

    The purpose of this study was to evaluate the real world situation and clarify the problem in initial treatment for elderly patients with ovarian cancer in Japan.

    Seiko Bun, Mayu Yunokawa, Takahiro Ebata… in International Journal of Clinical Oncology (2019)

  9. No Access

    Chapter

    Immunotherapy

    The prognosis of advanced small cell lung cancer and non-small cell lung cancer was improved with development of chemotherapy and molecular target therapy but still remains poor. Recently, immunotherapy, espec...

    Takahiro Ebata in Molecular Targeted Therapy of Lung Cancer (2017)

  10. No Access

    Article

    Feasibility of dose-dense paclitaxel/carboplatin therapy in elderly patients with ovarian, fallopian tube, or peritoneal cancer

    Weekly dose-dense paclitaxel (PTX) in combination with carboplatin (CBDCA) every 3 weeks (ddTC therapy) is a standard treatment for patients with advanced ovarian cancer. However, there is no detailed analysis...

    Seiko Bun, Mayu Yunokawa, Takahiro Ebata… in Cancer Chemotherapy and Pharmacology (2016)

  11. No Access

    Article

    p53 regulates cytoskeleton remodeling to suppress tumor progression

    Cancer cells possess unique characteristics such as invasiveness, the ability to undergo epithelial–mesenchymal transition, and an inherent stemness. Cell morphology is altered during these processes and this ...

    Keigo Araki, Takahiro Ebata, Alvin Kunyao Guo… in Cellular and Molecular Life Sciences (2015)